Protocol Ledger

NCT06544499 · Phase III · RECRUITING

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Interventional Phase III clinical trial protocol NCT06544499 sponsored by argenx in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-18 Enrollment: 69 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06544499
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)69 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06544499
Protocol FieldVerified Registry Value
NCT IdentifierNCT06544499
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment69 participants (ESTIMATED)
Registered Start Date2024-10-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI